Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO.

被引：0
|
作者：
Ambrosini, Margherita
Raimondi, Alessandra
Sabella, Giovanna
Cerantola, Riccardo
Palermo, Federica
Di Donato, Samantha
Spada, Daniele
Tamberi, Stefano
Perissinotto, Eleonora
Bergamo, Francesca
Passardi, Alessandro [1 ]
Tamburini, Emiliano [2 ]
Rosati, Riccardo [3 ]
Sartore-Bianchi, Andrea [4 ]
Guaglio, Marcello [5 ]
Cremolini, Chiara [6 ]
Montroni, Isacco [7 ]
Lonardi, Sara [8 ]
Pietrantonio, Filippo [9 ]
机构：
[1] IRCCS, Ist Romagnolo Studio Tumori IRST Dino Amadori, Meldola, Italy
[2] Cardinale Pan Tricase City Hosp, Oncol Dept & Palliat Care, Tricase, Italy
[3] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Milan, Italy
[4] ASST Grande Osped Metropolitano Niguarda, Dept Serv Immunohematol & Transfus Med, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Peritoneal Surface Malignancies Unit, Colorectal Surg, Milan, Italy
[6] Univ Pisa, Unit Med Oncol 2, Azienda Osped Univ Pisana, Pisa, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Colorectal Surg Unit, Milan, Italy
[8] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Med Oncol 1, Padua, Italy
[9] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.158
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：158 / 158
页数：1
相关论文
共 11 条
  • [1] Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update.
    Hissong, Erika
    Jafari, Mehraneh D.
    Khan, Sahrish
    Kasi, Pashtoon Murtaza
    Guniganti, Preethi
    Ocean, Allyson J.
    Siolas, Despina
    Yeo, Heather
    Khan, Uqba
    Pigazzi, Alessio
    Lutfi, Areeb
    Chen, Zhengming
    Shah, Manish A.
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 207 - 207
  • [2] Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).
    Fakih, Marwan
    Segal, Neil Howard
    Schlechter, Benjamin L.
    Andre, Thierry
    Pietrantonio, Filippo
    Johnson, Benny
    Vasilyev, Alexander
    Krishnamurthi, Smitha S.
    Siena, Salvatore
    Messersmith, Wells A.
    Silva, Virgilio
    Paulson, Andrew Scott
    Elez, Elena
    Eng, Cathy
    Tejpar, Sabine
    Ducreux, Michel Pierre
    Wu, Wei
    Grossman, Joseph Elan
    Van Cutsem, Eric
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 23 - 23
  • [3] Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
    Bullock, A.
    Fakih, M.
    Gordon, M.
    Tsimberidou, A.
    El-Khoueiry, A.
    Wilky, B.
    Pimentel, A.
    Margolin, K.
    Mahadevan, D.
    Balmanoukian, A.
    Sanborn, R.
    Schwartz, G.
    Abou-Alfa, G.
    Bockorny, B.
    Moser, J.
    Sharma, S.
    Grossman, J.
    Rosenthal, K.
    O'Day, S.
    Lenz, H.
    Schlechter, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S178 - S179
  • [4] Neoadjuvant XELOX chemotherapy with or without cadonilimab in locally advanced pMMR rectal cancer: Preliminary results from a randomized, open-label phase II trial
    Zhou, H.
    Gong, C.
    Zhang, J.
    Zou, S.
    Tang, J.
    Liang, J.
    Liu, Z.
    Zhang, W.
    Jiang, Z.
    Qu, W.
    Zhang, H.
    Zhao, Q.
    Sun, Y.
    Zhou, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S104 - S104
  • [5] Original Article Efficacy and Safety of Preoperative Transcatheter Rectal Arterial Chemoembolisation in Patients with Locally Advanced Rectal Cancer: Results from a Prospective, Phase II PCAR Trial
    Yang, W.
    Qian, C.
    Luo, J.
    Chen, C.
    Feng, Y.
    Dai, N.
    Li, X.
    Xiao, H.
    Yang, Y.
    Li, M.
    Li, C.
    Wang, D.
    CLINICAL ONCOLOGY, 2024, 36 (04) : 233 - 242
  • [6] Impact of the radiation regimen on local control and survival for patients with resectable locally advanced oesophageal cancer treated with chemoradiation: Results based on randomized phase III trial from the "Federation Francaise De Cancerologie Digestive"
    Maingon, P.
    Bonnetain, F.
    Seng, S-H.
    N'Guyen, T. D.
    Mirabell, X.
    Marchal, C.
    Verrelle, P.
    Roullet, B.
    Resbeut, M.
    Janoray, P.
    Bedenne, L.
    Crehange, G.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S193 - S194
  • [7] Preoperative intensified chemoradiotherapy with or without induction chemotherapy in patients with locally advanced rectal cancer and synchronous liver-limited resectable metastases; result from a randomized phase II study to improve both local and systemic control.
    Park, Seong Joon
    Hong, Yong Sang
    Kim, Jeong Eun
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Lee, Myung Ah
    Chun, Hoo Geun
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Impact of radiation (RT) regimen on palliative procedures (PP) for patients with resectable locally advanced esophageal cancer treated with exclusive chemoradiation (CRT) or preoperative chemoradiation (CRT plus S): results from a phase III trial of the Federation Francophone de Cancerologie Digestive (FFCD 9102)
    Crehange, G.
    Bonnetain, F.
    Seng, S.
    N'guyen, T.
    Mirabel, X.
    Marchal, C.
    Verrelle, P.
    Roullet, B.
    Maingnon, P.
    Bedenne, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase II randomized trial of capecitabine 1 radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival
    Gravalos, C.
    Capdevila, J.
    Layos, L.
    Pericay, C.
    Martinez-Villacampa, M.
    Lopez Lopez, C.
    Losa, F.
    Safont, M. J.
    Gomez-Espana, A.
    Alonso, V.
    Escudero, P.
    Gallego, J.
    Garcia-Paredes, B.
    Palacios, A.
    Biondo, S.
    Salazar, R.
    Aranda Aguilar, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Split course or protracted radiotherapy combined with cisplatin (CDDP) and fluorouracile (5-FU) for patients with resectable locally advanced esophageal cancer: Results based on a randomized phase III trial from the fondation francaise de cancerologie digestive: FFCD no. 9102.
    Crehange, G.
    Bonnetain, F.
    Seng, S.
    Nguyen, T.
    Mirabel, X.
    Marchal, C.
    Verrelle, P.
    Roullet, B.
    Bedenne, L.
    Maingon, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S79 - S79
12